AR089812A1 - THERAPEUTIC AGENT FOR MELLITUS DIABETES - Google Patents

THERAPEUTIC AGENT FOR MELLITUS DIABETES

Info

Publication number
AR089812A1
AR089812A1 ARP130100233A ARP130100233A AR089812A1 AR 089812 A1 AR089812 A1 AR 089812A1 AR P130100233 A ARP130100233 A AR P130100233A AR P130100233 A ARP130100233 A AR P130100233A AR 089812 A1 AR089812 A1 AR 089812A1
Authority
AR
Argentina
Prior art keywords
group
therapeutic agent
formula
mellitus diabetes
therapeutic
Prior art date
Application number
ARP130100233A
Other languages
Spanish (es)
Original Assignee
Teijin Pharma Ltd
Nat Univ Corp Tottori Univ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teijin Pharma Ltd, Nat Univ Corp Tottori Univ filed Critical Teijin Pharma Ltd
Publication of AR089812A1 publication Critical patent/AR089812A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Reivindicación 1: Un agente terapéutico o profiláctico para enfermedades causadas por trastornos del metabolismo de la glucosa que comprende, como ingrediente activo, un compuesto de 2-feniltiazol representado por la fórmula (1) o una sal farmacéuticamente aceptable del mismo, (en la fórmula, en la cual R¹ representa un grupo alcoxi C₁₋₈, un grupo morfolino, un grupo 4-metilpiperazin-1-ilo, o un grupo piperidino, R² representa un grupo nitro o un grupo ciano, X representa un grupo carboxilo o un grupo alcoxicarbonilo C₂₋₇, Y representa un átomo de hidrógeno o un grupo alquilo C₁₋₆).Claim 1: A therapeutic or prophylactic agent for diseases caused by disorders of glucose metabolism comprising, as an active ingredient, a 2-phenylthiazole compound represented by the formula (1) or a pharmaceutically acceptable salt thereof, (in the formula , in which R¹ represents a C₁₋₈ alkoxy group, a morpholino group, a 4-methylpiperazin-1-yl group, or a piperidino group, R² represents a nitro group or a cyano group, X represents a carboxyl group or a group C₂₋₇ alkoxycarbonyl, Y represents a hydrogen atom or a C₁₋₆ alkyl group).

ARP130100233A 2012-01-27 2013-01-25 THERAPEUTIC AGENT FOR MELLITUS DIABETES AR089812A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2012015351 2012-01-27

Publications (1)

Publication Number Publication Date
AR089812A1 true AR089812A1 (en) 2014-09-17

Family

ID=48873581

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130100233A AR089812A1 (en) 2012-01-27 2013-01-25 THERAPEUTIC AGENT FOR MELLITUS DIABETES

Country Status (15)

Country Link
US (1) US20150005506A1 (en)
EP (1) EP2808018B1 (en)
JP (1) JP5924699B2 (en)
KR (1) KR20140134266A (en)
CN (1) CN104066430A (en)
AR (1) AR089812A1 (en)
AU (1) AU2013212865A1 (en)
BR (1) BR112014017902A2 (en)
CA (1) CA2862602A1 (en)
HK (1) HK1201209A1 (en)
IN (1) IN2014DN05972A (en)
MX (1) MX2014008484A (en)
RU (1) RU2014134845A (en)
TW (1) TW201334779A (en)
WO (1) WO2013111870A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104610190B (en) * 2015-02-10 2016-08-17 佛山市赛维斯医药科技有限公司 One class contains halogenophenyl thiazole carboxylic acid amides's compounds and the purposes of cyclopropyl amidine structure
CN104628672A (en) * 2015-02-10 2015-05-20 佛山市赛维斯医药科技有限公司 Alkoxyphenylthiazole carboxylic acid amide compounds containing phenylamidine structures and application
CN104628673A (en) * 2015-02-10 2015-05-20 佛山市赛维斯医药科技有限公司 Nitrile benzene thiazolecarboxamide type compound containing tert-butylamidine structure and application thereof
CN104610188B (en) * 2015-02-10 2016-07-27 佛山市赛维斯医药科技有限公司 Itrile group benzene thiazole carboxylic acid amides's compounds containing benzene carbon amidine structure, its preparation and purposes
CN104628671B (en) * 2015-02-10 2016-04-13 佛山市赛维斯医药科技有限公司 Containing oil of mirbane thiazole carboxylic acid amides compounds and the purposes of benzene carbon amidine structure
KR102473677B1 (en) * 2015-08-17 2022-12-02 삼성디스플레이 주식회사 Liquid crystal display
AR107661A1 (en) 2016-02-19 2018-05-23 Nat Univ Corp Tottori Univ THERAPEUTIC OR PROFILACTIC AGENT FOR DEMENTIA

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG86971A1 (en) * 1990-11-30 2002-03-19 Teijin Ltd 2-arylthiazole derivatives and pharmaceutical composition thereof
HUP9902721A2 (en) * 1997-11-25 1999-12-28 The Procter & Gamble Co. Concentrated fabric softening composition and highly unsaturated fabric softener compound therefor
US20050074442A1 (en) * 2002-03-13 2005-04-07 Natarajan Ranganathan Compositions and methods for augmenting kidney function
US8557831B2 (en) * 2004-07-21 2013-10-15 University Of Florida Research Foundation, Inc. Compositions and methods for treatment and prevention of insulin resistance
EP1919472B1 (en) * 2005-07-21 2021-09-01 University of Florida Research Foundation, Inc. Compositions and methods for treatment and prevention of hyperuricemia related health consequences
CA2617248C (en) 2005-08-03 2015-09-29 Tap Pharmaceutical Products, Inc. Methods for treating hypertension
EP1957064A4 (en) * 2005-11-21 2010-01-06 Tap Pharmaceutical Prod Inc Treatment of qt interval prolongation and diseases associated therewith
JP2007210978A (en) * 2006-02-13 2007-08-23 Hiroshima Univ Agent for preventing/treating glucose tolerance dysfunction, type ii diabetes, hyperlipemia, metabolic syndrome, visceral fat obesity, fatty liver or non-alcoholic fatty hepatitis
CN101677999A (en) 2006-11-13 2010-03-24 塔普医药产品公司 Methods for preserving renal function using xanthine oxidoreductase inhibitors
ME01294B (en) * 2007-11-27 2013-06-20 Ardea Biosciences Inc Novel compounds and compositions and methods of use
BRPI0909691B1 (en) * 2008-03-31 2021-07-20 C&C Research Laboratories COMPOUND DERIVED FROM HETEROCYCLE, METHOD FOR PREPARING A COMPOUND, AND PHARMACEUTICAL COMPOSITION
US8410154B2 (en) * 2008-04-30 2013-04-02 Wellstat Therapeutics Corporation Tetrazole compounds for reducing uric acid
CA2725047A1 (en) * 2008-05-22 2009-11-26 Bristol-Myers Squibb Company Method for treating hyperuricemia employing an sglt2 inhibitor and composition containing same
US20110257202A1 (en) * 2008-10-19 2011-10-20 Richard J Johnson Therapeutic Compositions and Methods for Treating Chronic Kidney Disease Associated with a Metabolic Imbalance
EP2470268A4 (en) * 2009-08-24 2012-12-26 Wound Man Pty Ltd Purine-targeted diagnosis and therapy of wounds
AU2011268445B2 (en) * 2010-06-16 2015-05-07 Takeda Pharmaceuticals U.S.A., Inc. Novel modified release dosage forms of xanthine oxidoreductase inhibitor or xanthine oxidase inhibitors
TW201215389A (en) * 2010-06-25 2012-04-16 Teijin Pharma Ltd Sustained-release therapeutic agent for hypertension and renal dysfunction

Also Published As

Publication number Publication date
EP2808018A4 (en) 2015-07-15
TW201334779A (en) 2013-09-01
HK1201209A1 (en) 2015-08-28
RU2014134845A (en) 2016-03-20
JPWO2013111870A1 (en) 2015-05-11
EP2808018A1 (en) 2014-12-03
WO2013111870A1 (en) 2013-08-01
AU2013212865A1 (en) 2014-08-14
IN2014DN05972A (en) 2015-06-26
EP2808018B1 (en) 2018-03-14
CA2862602A1 (en) 2013-08-01
CN104066430A (en) 2014-09-24
MX2014008484A (en) 2014-10-14
KR20140134266A (en) 2014-11-21
BR112014017902A2 (en) 2017-08-22
JP5924699B2 (en) 2016-05-25
US20150005506A1 (en) 2015-01-01

Similar Documents

Publication Publication Date Title
AR089812A1 (en) THERAPEUTIC AGENT FOR MELLITUS DIABETES
AR092661A1 (en) REINFORCED KINASE INHIBITOR DURING TRANSFECTION (RET) AND A METHOD FOR IDENTIFYING A SENSITIVE PATIENT TO A COMPOSITE REPRESENTED BY FORMULA (1)
AR093093A1 (en) TREATMENTS AND PROFILAXIS FOR THE TUMOR LISIS SYNDROME
CY1119707T1 (en) DIABLIC AMID CARE UNITS AS MODELS
PH12015502628B1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of disease
EA201690020A1 (en) APPLICATION OF PYRAZOLOPIRIDINE DERIVATIVES FOR THE TREATMENT OF URINARY BUBBLE CANCER
EA201690223A1 (en) FACTOR INHIBITORS IN THE COMPLEMENT BASED ON PIPERIDININILINDOL DERIVATIVES AND THEIR APPLICATION
CR20120448A (en) HETEROCYCLIC COMPOUND
EA201592256A1 (en) DERIVATIVES OF IMIDAZOPIRROLIDINONE AND THEIR APPLICATION IN THE TREATMENT OF DISEASES
DOP2006000170A (en) NEW DERIVATIVES OF ESPIROCROMANONA
EA201492023A1 (en) REGULATORS OF THE COMPLEX WAY AND THEIR APPLICATION
UY32816A (en) PHARMACEUTICAL FORMULATION BASED ON 1- [2- (2,1,3-BENZOTIADIAZOL-5-ILAMINO) -6 (2,6-DICLOROFENIL) -PIRIDO [2,3-D] PIRIMIDIN-7-IL] -3- TERT-BUTIL-URÉA
EA201590200A1 (en) MODULATORS OF THE COMPLEMENT ACTIVATION WAY AND THEIR APPLICATION
NZ703989A (en) Alkoxy pyrazoles as soluble guanylate cyclase activators
CO6531458A2 (en) NEW SPYROPIPERIDINE COMPOUNDS
EA201492290A1 (en) COMPOSITIONS AND METHODS FOR VAGINAL DELIVERY OF ANTIPROGHESTINES
PH12014501967B1 (en) Benzodioxanes in combination with other actives for inhibiting leukotriene production
MX2015016421A (en) Pyrazolo-pyrrolidin-4-one derivatives as bet inhibitors and their use in the treatment of disease.
CO6491060A2 (en) COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITARY DISEASES
ECSP12011930A (en) NEW SPYROPIPERIDINE COMPOUNDS
CU20150084A7 (en) ACID DERIVATIVES 4 - ((1,1) BISFENIL -4-IL) -3- (3-PHOSPHONOPROPANAMIDE) BUTANOIC, ACTIVE AS NEP INHIBITORS (NEUTRAL ENDOPEPTIDASE)
AR085616A1 (en) INHALABLE PHARMACEUTICAL COMPOSITION UNDERSTANDING GLICOPIRROLATE, USE
WO2014107730A3 (en) Use of fatty acid niacin conjugates for treating diseases
PH12016500577A1 (en) Piperazine derivatives and the use thereof as medicament
AR088287A1 (en) THERAPEUTICAL AGENT AND PREVENTIVE AGENT FOR DEMIELINIZING DISEASE

Legal Events

Date Code Title Description
FB Suspension of granting procedure